DOCSLIB.ORG

Ketamine: an Update on the First Twenty-Five Years of Clinical

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ketamine: an Update on the First Twenty-Five Years of Clinical 186 Special Article Ketamine: an update on the first twenty-five years of clinical David L. Reich MD, George Silvay MD PhO experience Contents Ketamine is a dissociative anaesthetic agent that has Pharmacology acquired an unique place in clinical practice. Since the - Pharmacokinetics first published report of its clinical use ~an understanding - Pharmacodynamics of its anaesthetic, analgesic, and amnestic qualities has - Mechanism of action - N-methyl-aspartate receptor theory grown from extensive clinical and laboratory research. - Opiate receptor theory The initial experience with ketamine as a sole anaesthetic - Miscellaneous receptor theory agent led to the recognition of unpleasant emergence Central nervous system effects reactions and cardiovascular stimulant properties, which - Eleetroencephalographic effects limited its usefulness. However, supplementation with - lntracranial pressure other drugs such as the benzodiazepines have reduced - Emergence phenomena Cardiovascular effects these side effects. Previous reviewersz'J have detailed the - Mechanism early work on the pharmacology and clinical uses of - Effects on rhythm ketamine. This review encompasses the more recent - Prevention of cardiovascular stimulation research on ketamine, and emphasizes human data. - lschaemic heart disease Ketamine's role in clinical anaesthesia is changing as a - Cardiovascular effects in children and neona~s Respiratory effects result of the evolving concepts of its mechanism of action - Respiratory pattem and the advantages of alternative routes of administration. - Hypoxic pulmonary vasoconstriction - Bronchodilation - Airway maintenance Optical isomers Pharmacology Other pharmacologic effects Ketamine [KETALAR~, KETAJECT| is chemically - Neuromuscular blockade related to phencyclidine (PCP) and cyclohexamine, it - Endocrine/metabolic response has a molecular weight of 238 and a pKa of 7.5. Although Effects on intraocular pressure ketamine hydrochloride is water soluble, ketamine's lipid - Effects on coagulation Clinical uses solubility is ten times that of thiopentone. The molecular - Epidural and intrathecal ketamine structure (2-(O-chloropheny l)-2-methylamino cyclohex- - Oral and rectal ketamine anone) contains a chiral centre at the C-2 carbon of the - Obstetrics cyclohexanone ring so that two enantiomers of the Paediatrie radiation therapy and burn patients ketamine molecule exist: s(+)ketamine and r(-)keta- - Outpatient anaesthesia mine. Commercially available racemic ketamine prep- - Critically ill patients - Cardiac surgery arations contain equal concentrations of the two enan- - Miscellaneous topics tiomers. These enantiomers differ in anaesthetic potency, Summary in the responses of the electroencephalograph (EEG), in Key words effects on catecholamine reuptake, and possibly in the incidence of emergence reactions. ANAESTHETICS,INTRAVENOUS: ketamine. From the Department of Anacsthcsiology, Box 1010, Mount Pharmacokinetics Sinai Medical Center, One Gustavc L. Levy Place, New Ketamine has a high bioavailability following intravenous York, New York 10029 U.S.A. or intramuscular administration. First-pass metabolism Address correspondence to: Dr. D. L. Reich. and lower absorption necessitate higher dosages when CAN J ANAESTH 1989 ! 36:2 / pp 186-97 Reich and Silvay: KETAMINE, TWENTY-FIVE YEARS CLINICAL EXPERIENCE 187 ketamine is administered by the oral or rectal routes (vide high concentrations of ketamine for intravenous regional infra). Biotransformation takes place in the liver, and anaesthesia and subarachnoid block, m,~ multiple metabolites have been described. The most important pathway involves N-demethylation by cyto- Mechanism of action chrome P4so to norketamine, an active metabolite with The anaesthetic state produced by ketamine was original- an anaesthetic potency one third that of ketamine. Nor- ly described as a functional and electrophysiological ketamine (originally termed metabolite I in the earlier dissociation between the thalamoneocortical and limbic literature) is then hydroxylated and conjugated to water systems. Ketamine as the sole anaesthetic produces a soluble compounds that are excreted in the urine. The cataleptic state with nystagmus and intact corneal and cyclohexanone ring also undergoes oxidative metabo- light reflexes. Hypertonus, purposeful movements and lism. Earlier literature listed dehydronorketamine (meta- vocalization may occur. bolite I1) as an important breakdown product of ketamine, Ketamine is a potent analgesic at subanaesthetie plasma but this compound is most likely an artifact of the concentrations, and its analgesic and anaesthetic effects chromatographic analysis, and not an important meta- may be mediated by different mechanisms. The analgesia bolite in vivo. 4 may be due to an interaction between ketamine and central Ketamine pharmacokinetics follow a three-term or spinal opiate receptors. ~: exponential decline. In unpremedicated patients, distribu- tion half-life (h12~') was 24.1 seconds, redistribution half-life (h/2a) was 4.68 minutes, and elimination half- N-METHYL-ASPARTATE RECEPTOR THEORY life (h~213) was 2.17 hours. 5 Pharmacokinetics were sim- N-methyl-aspartate (NMA) is an excitatory amine, and its ilar in children, except that absorption was more rapid receptors in mammalian brain are blocked by PCP and following intramuscular administration, and higher con- ketamine, t3'~4 The NMA receptors may represent a centrations of norketamine were present. 6 Diazepam subgroup of the sigma opiate receptors ("the PCP site") seems to inhibit the hepatic metabolism of ketamine, but that block spinal nociceptive reflexes. IS Ketamlne also etomidate does not. 7 blocks NMA-induced seizures at high doses, and NMA- induced behavioural changes at lower doses in the rat model. Js Metaphit, a recently synthesized piperidine derivative, Pharmacodynamics The pharmacodynamic effect of ketamine in humans is blocks the action of NMA by acetylating the receptors. It apparently due to the CNS activity of the parent com- was hoped that metaphit might displace ketamine from pound. As CNS levels of ketaminc decline by redistribu- NMA receptors and reverse ketamine anaesthesia. How- tion to the peripheral compartment, the CNS effects ever, metaphit acts as an agonist/antagonist at the recep- subside, although not as rapidly as would be predicted tors, and does not reverse dissociative anaesthesia in fl~e rat model. ~7 from its high lipid solubility,s Decreased renal fnnction, and the presence of active metabolites, do not prolong the drug's action. Tolerance and hepatic enzyme induction OPIATE RECEPTOR THEORY have been reported following chronic administration. Ketamine's affinity for opiate receptors is controversial, Both halothane and diazepam prolong the clinical but this provides an attractive theory for its analgesic anaesthetic effect of ketamine. However, it is not clear activity at central and spinal sites. Smith et al. showed whether this is due to the synergistic effects of CNS that racemic ketamine displaced tritiated naloxone from depressant drugs, decreased ketamine clearance, or a rat brain opiate receptors in vitro, and that (+)ketamine combination of these factors. Diazepam causes an in- was about twice as potent as (-)ketamine for this crease in plasma ketamine levels, but also a prolongation purpose. 18 Finck and Ngai not only confirmed the above of tu2a and tlt213 in humans. study, but also found similar stereospecific opiate recep- Analgesia from ketamine is associated with a plasma tor binding by (+)ketamine in guinea pig ileum in vitro, t9 concentration of 0.15 ~g. ml-t following intramuscular Cross-tolerance between the opiates and ketamine would administration, and 0.04 v,g" ml-J following oral admin- also be expected if there is a common receptor. This has istration. The difference in the analgesic plasma concen- now been shown in two independent animal studies. 2~ trations might be explained by a higher norketamine The opiate receptor theory would gain more credence if concentration following oral administration (probably ketamine reversal by naloxone were proven in humans. from first-pass metabolism), which contributes to the Stella et al. reported that none of 68 adult patients analgesia. Awakening from ketamine anaesthesia takes premedicated with naloxone lost consciousness following place at plasma concentrations of 0.64-1.12 p,g- ml- ~.9 the administration of EDso doses of ketamine. 22 Amiot et Both sensory and motor block occur in humans using al. repeated the doses used in the above study, but in 188 CANADIAN JOURNAL OF ANAESTHESIA pregnant patients whose anaesthetic requirements may and found no further increase in ICP with 0.5 or 2.0 have been lower, and without a control group. They found mg.kg-~ of IV ketamine. 36 It was also hypothesized in no evidence of naloxone reversal of ketamine at a similar earlier studies, thai ketamine increased ICP due to a direct dosagefl 3 cerebral vasodilatory action. However, Schwedler et al. injected ketamine directly into cerebral vessels, and found MISCELLANEOUS RECEPTOR THEORY no effects on the vasculature. 37 Anterior fontanelle pres- Other neuronal systems may be involved in the antinoci- sure, an indirect monitor of ICP, declined by I 0 per cent ceptive action of ketamine, since blockade of noradrena- in mechanically ventilated preterm neonates following line and serotonin receptors attenuates the analgesic 2 mg "kg-~ of IV ketamine. 3s action of ketamine in animals. 2a Interaction of kctamine with sigma opiate
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Postoperative Pain
    LONDON, SATURDAY 19 AUGUST 1978 MEDICAL Br Med J: first published as 10.1136/bmj.2.6136.517 on 19 August 1978. Downloaded from JOURNAL Postoperative pain It is an indictment of modern medicine that an apparently carries marginally less risk of depressing respiration or of simple problem such as the reliable relief of postoperative inducing nausea or vomiting. Nevertheless, it does produce pain remains largely unsolved. Numerous patients will bear psychotomimetic side effects, which are related to the dose. testimony to our shortcomings: indeed, after talking to their These reduce its value in the prolonged treatment of very friends, many will expect pain after their operation. At whose severe pain. door can we lay the responsibility-the patients, the doctors, Meptazinol is a new opiate antagonist which produces the nurses, or the pharmaceutical industry ? postoperative analgesia similar to that obtained with pethidine The patients themselves must take a fair share of the and pentazocine.4 Its potency, milligram for milligram, is blame. In no symptom are they more inconsistent and un- similar to pethidine's but its action and sedative effect are reliable. After identical operations under identical anaesthetics somewhat shorter. Cardiovascular performance is not reduced carried out by the same specialists, two patients in the same and respiration is thought to be less affected than with ward may apparently experience entirely different degrees pethidine. The main potential advantage, however, is that in of pain. Personality differences may account for some of the animal studies it has shown a low dependence potential.5 If variations, but we certainly do not understand these well these non-addictive properties are confirmed in man and enough confidently to provide each individual with exactly further clinical trials show no psychotomimetic side effects, http://www.bmj.com/ what he or she needs.
    [Show full text]
  • Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G
    Veterinary Anesthetic and Analgesic Formulary 3rd Edition, Version G I. Introduction and Use of the UC‐Denver Veterinary Formulary II. Anesthetic and Analgesic Considerations III. Species Specific Veterinary Formulary 1. Mouse 2. Rat 3. Neonatal Rodent 4. Guinea Pig 5. Chinchilla 6. Gerbil 7. Rabbit 8. Dog 9. Pig 10. Sheep 11. Non‐Pharmaceutical Grade Anesthetics IV. References I. Introduction and Use of the UC‐Denver Formulary Basic Definitions: Anesthesia: central nervous system depression that provides amnesia, unconsciousness and immobility in response to a painful stimulation. Drugs that produce anesthesia may or may not provide analgesia (1, 2). Analgesia: The absence of pain in response to stimulation that would normally be painful. An analgesic drug can provide analgesia by acting at the level of the central nervous system or at the site of inflammation to diminish or block pain signals (1, 2). Sedation: A state of mental calmness, decreased response to environmental stimuli, and muscle relaxation. This state is characterized by suppression of spontaneous movement with maintenance of spinal reflexes (1). Animal anesthesia and analgesia are crucial components of an animal use protocol. This document is provided to aid in the design of an anesthetic and analgesic plan to prevent animal pain whenever possible. However, this document should not be perceived to replace consultation with the university’s veterinary staff. As required by law, the veterinary staff should be consulted to assist in the planning of procedures where anesthetics and analgesics will be used to avoid or minimize discomfort, distress and pain in animals (3, 4). Prior to administration, all use of anesthetics and analgesic are to be approved by the Institutional Animal Care and Use Committee (IACUC).
    [Show full text]
  • Medication Safety in High-Risk Situations
    Medication Safety in High-risk Situations Technical Report Medication Safety in High-risk Situations Technical Report WHO/UHC/SDS/2019.10 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules). Suggested citation. Medication Safety in High-risk Situations. Geneva: World Health Organization; 2019 (WHO/UHC/SDS/2019.10). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • Opioid Analgesics and the Gastrointestinal Tract
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #64 Carol Rees Parrish, R.D., M.S., Series Editor Opioid Analgesics and the Gastrointestinal Tract Lingtak-Neander Chan Opioids have been used to manage pain and other ailments for centuries. The consti- pating effects of opioid analgesic agents are well known and can be used to manage severe diarrhea and control high output ostomies. Loperamide, diphenoxylate, and difenoxin are currently the only opioid-derivatives approved by the FDA for treating diarrhea. Drug-drug interactions and end organ dysfunction may exacerbate systemic side effects of these drugs. In patients who have failed to respond to these agents, other systemic opioids may be considered. The goal of therapy to control gastrointestinal secretion should be to use the lowest effective dose with minimal side effects. Careful monitoring for systemic side effects during the initiation and dose titration phase are crucial to minimize the risks associated wtih opioid use. INTRODUCTION Sumerian clay tablets inscribed in Cuneiform script he term “opioid” refers to a large group of com- about 3000 B.C. Opium was probably used as an pounds and chemicals that share the characteris- euphoriant in religious rituals by the Sumerians (1,2). Ttics of opium. Opium, from the Greek word During the Middle Ages, after opium was introduced “opos” for juice, refers to the liquid collected from the to Asia and Europe, more extensive documentation of unripe seed capsule of Papaver somniferum L., also opium use became available. It wasn’t until 1805, that known as opium poppy. Opium has been used for med- a young German apothecary named Friedrich Wilhelm icinal purposes for centuries.
    [Show full text]
  • In Collaboration with the World Health Organization
    in collaboration with the World Health Organization DELIVER DELIVER, a five-year worldwide technical assistance support contract, is funded by the Commodities Security and Logistics Division (CSL) of the Office of Population and Reproductive Health of the Bureau for Global Health (GH) of the U.S. Agency for International Development (USAID). Implemented by John Snow, Inc. (JSI), (contract no. HRN-C-00-00-00010-00), and subcontractors (Manoff Group; Program for Appropriate Technology in Health [PATH]; Social Sectors Development Strategies, Inc.; Synaxis, Inc.; Boston University Center for International Health; Crown Agents Consultancy, Inc.; Harvard University Health Systems Group; and Social Sectors Development Strategies), DELIVER strengthens the supply chains of health and family planning programs in developing countries to ensure the availability of critical health products for customers. DELIVER also provides technical support to USAID’s central contraceptive procurement and management, and analysis of USAID’s central commodity management information system (NEWVERN). This document does not necessarily represent the views or opinions of USAID or the World Health Organization. It may be reproduced if credit is given to John Snow, Inc./DELIVER. Recommended Citation John Snow, Inc./DELIVER in collaboration with the World Health Organization. Guidelines for the Storage of Essential Medicines and Other Health Commodities. 2003. Arlington, Va.: John Snow, Inc./DELIVER, for the U.S. Agency for International Development. Abstract Maintaining proper storage conditions for health commodities is vital to ensuring their quality. Product expiration dates are based on ideal storage conditions and protecting product quality until their expiration date is important for serving customers and conserving resources. Guidelines for the Storage of Essential Medicines and Other Health Commodities is a practical reference for those managing or involved in setting up a storeroom or warehouse.
    [Show full text]
  • A Case of Codeine Induced Anaphylaxis Via Oral Route Hye-Soo Yoo, Eun-Mi Yang, Mi-Ae Kim, Sun-Hyuk Hwang, Yoo-Seob Shin, Young-Min Ye, Dong-Ho Nahm, Hae-Sim Park*
    Case Report Allergy Asthma Immunol Res. 2014 January;6(1):95-97. http://dx.doi.org/10.4168/aair.2014.6.1.95 pISSN 2092-7355 • eISSN 2092-7363 A Case of Codeine Induced Anaphylaxis via Oral Route Hye-Soo Yoo, Eun-Mi Yang, Mi-Ae Kim, Sun-Hyuk Hwang, Yoo-Seob Shin, Young-Min Ye, Dong-Ho Nahm, Hae-Sim Park* Department of Allergy & Clinical Immunology, Ajou University School of Medicine, Suwon, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Codeine is widely prescribed in clinical settings for the relief of pain and non-productive coughs. Common adverse drug reactions to codeine include constipation, euphoria, nausea, and drowsiness. However, there have been few reports of serious adverse reactions after codeine ingestion in adults. Here, we present a case of severe anaphylaxis after oral ingestion of a therapeutic dose of codeine. A 30-year-old Korean woman complained of the sudden onset of dyspnea, urticaria, chest tightness, and dizziness 10 minutes after taking a 10-mg dose of codeine to treat a chronic cough follow- ing a viral infection. She had previously experienced episodes of asthma exacerbation following upper respiratory infections, and had non-atopic rhi- nitis and a food allergy to seafood. A skin prick test showed a positive response to 1-10 mg/mL of codeine extract, with a mean wheal size of 3.5 mm, while negative results were obtained in 3 healthy adult controls.
    [Show full text]
  • OPIUM Latest Revision: June 30, 2000
    OPIUM Latest Revision: June 30, 2000 1. SYNONYMS CFR: Opium CAS #: Codeine Base: 76-57-3 Codeine Hydrochloride: 1422-07-7 Morphine Base: 57-27-2 Morphine Hydrochloride: 52-26-6 Thebaine Base: 115-37-7 Noscapine Base: 128-62-1 Noscapine Hydrochloride: 912-60-7 Papaverine Base: 58-74-2 Papaverine Hydrochloride: 61-25-6 Other Names: Oil poppy Opium poppy 2. CHEMICAL AND PHYSICAL DATA The immediate precursor of heroin is morphine, and morphine is obtained from opium. Opium is the dried milky juice (latex) obtained from the unripe seed pods of Papaver somniferum L., more commonly referred to as the opium poppy or oil poppy. Morphine has also been reported to be present in Papaver setigerum, and as a minor alkaloid in Papaver decaisnei and Papaver rhoeas. However, there is no known instance of these poppies being used for opium production, and work that is more recent has cast considerable doubt as to the presence of morphine in Papaver rhoeas. A major review by Kapoor on the botany and chemistry of the opium poppy is recommended additional reading. Opium latex is obtained from the seed capsule of the poppy while the capsule is still in the green stage, usually seven or more days after flowering and petal fall. Physically, the opium latex is contained within laticiferous vessels, which lie just beneath the epicarp of the seed capsule. The latex is harvested by making a series of shallow incisions through the epicarp, which allows the latex to "bleed" onto the surface of the seed capsule. Most commonly, the latex is allowed to partially dry on the capsule surface, and is then removed by scraping the capsule with specially designed hand tools.
    [Show full text]
  • Summary of Product Characteristics
    Revised: August 2018 AN: 00451/2018 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetergesic Multidose, 0.3 mg/ml Solution for Injection for Dogs, Cats and Horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Buprenorphine 0.3mg As Buprenorphine hydrochloride 0.324mg Excipient(s): Chlorocresol 1.35mg For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Solution for injection Clear, colourless solution for injection 4. CLINICAL PARTICULARS 4.1 Target species Dogs, cats and horses 4.2 Indications for use, specifying the target species Post-operative analgesia in the dog, cat and horse. Potentiation of the sedative effects of centrally-acting agents in the dog and horse. When used in horses, an intravenous sedative should be administered within five minutes prior to injection of buprenorphine. 4.3 Contraindications Do not administer by the intrathecal or peridural route. Do not use pre-operatively for Caesarian section (see Section 4.7). Not to be used in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation. 4.4 Special warnings None Page 1 of 8 Revised: August 2018 AN: 00451/2018 4.5 Special precautions for use i) Special precautions for use in animals Buprenorphine may cause respiratory depression and as with other opioid drugs, care should be taken when treating animals with impaired respiratory function or animals that are receiving drugs that can cause respiratory depression. In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk associated with the use of the product.
    [Show full text]
  • Acute Toxic Effects of Club Drugs
    Club drugs p. 1 © Journal of Psychoactive Drugs Vol. 36 (1), September 2004, 303-313 Acute Toxic Effects of Club Drugs Robert S. Gable, J.D., Ph.D.* Abstract—This paper summarizes the short-term physiological toxicity and the adverse behavioral effects of four substances (GHB, ketamine, MDMA, Rohypnol®)) that have been used at late-night dance clubs. The two primary data sources were case studies of human fatalities and experimental studies with laboratory animals. A “safety ratio” was calculated for each substance based on its estimated lethal dose and its customary recreational dose. GHB (gamma-hydroxybutyrate) appears to be the most physiologically toxic; Rohypnol® (flunitrazepam) appears to be the least physiologically toxic. The single most risk-producing behavior of club drug users is combining psychoactive substances, usually involving alcohol. Hazardous drug-use sequelae such as accidents, aggressive behavior, and addiction were not factored into the safety ratio estimates. *Professor of Psychology, School of Behavioral and Organizational Sciences, Claremont Graduate University, Claremont, CA. Please address correspondence to Robert Gable, 2738 Fulton Street, Berkeley, CA 94705, or to [email protected]. Club drugs p. 2 In 1999, the National Institute on Drug Abuse launched its Club Drug Initiative in order to respond to dramatic increases in the use of GHB, ketamine, MDMA, and Rohypnol® (flunitrazepam). The initiative involved a media campaign and a 40% increase (to $54 million) for club drug research (Zickler, 2000). In February 2000, the Drug Enforcement Administration, in response to a Congressional mandate (Public Law 106-172), established a special Dangerous Drugs Unit to assess the abuse of and trafficking in designer and club drugs associated with sexual assault (DEA 2000).
    [Show full text]
  • WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/006004 Al 9 January 2014 (09.01.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/20 (2006.01) A61K 31/485 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2013/06385 1 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, 1 July 20 13 (01 .07.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2012 70405 6 July 2012 (06.07.2012) DK (84) Designated States (unless otherwise indicated, for every 61/668,741 6 July 2012 (06.07.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: EGALET LTD.
    [Show full text]
  • List of Narcotic Drugs Under International Control
    International Narcotics Control Board YYeellllooww LLiisstt Annex to Forms A, B and C 50th edition, December 2011 LIST OF NARCOTIC DRUGS UNDER INTERNATIONAL CONTROL Prepared by the INTERNATIONAL NARCOTICS CONTROL BOARD* Vienna International Centre P.O. Box 500 A-1400 Vienna, Austria Internet address: http://www.incb.org/ in accordance with the Single Convention on Narcotic Drugs, 1961** Protocol of 25 March 1972 amending the Single Convention on Narcotic Drugs, 1961 ___________ * On 2 March 1968, this organ took over the functions of the Permanent Central Narcotics Board and the Drug Supervisory Body, retaining the same secretariat and offices. ** Subsequently referred to as “1961 Convention”. Purpose The Yellow List contains the current list of narcotic drugs under international control and additional relevant information. It has been prepared by the International Narcotics Control Board to assist Governments in completing the annual statistical reports on narcotic drugs (Form C), the quarterly statistics of imports and exports of narcotic drugs (Form A) and the estimates of annual requirements for narcotic drugs (Form B) as well as related questionnaires. The Yellow List is divided into four parts: Part 1 provides a list of narcotic drugs under international control in form of tables and is subdivided into three sections: (1) the first section includes the narcotic drugs listed in Schedule I of the 1961 Convention and/or Group I of the 1931 Convention; (2) the second section includes the narcotic drugs listed in Schedule II of the 1961 Convention and/or Group II of the 1931 Convention; and (3) the third section includes the narcotic drugs listed in Schedule IV of the 1961 Convention and/or Group II of the 1931 Convention.
    [Show full text]